

## PHARMACOKINETIC PROFILE OF TROGARZOTM PRESENTED AT IDWEEK

October 3, 2018

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that pharmacokinetic data from the pivotal phase III clinical trial for Trogarzo<sup>TM</sup> (ibalizumab-uiyk) injection will be presented tomorrow at IDWeek<sup>TM</sup> in San Francisco.